Statistics Collaborative - Design and analysis for biomedical research

PublicationsPublications

Heidi Christ-Schmidt

  • Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17:1057-1065.
  • Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS Inhibitors. N Engl J Med 2015; 372:211-221.
  • de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:2492-2503.

  • Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial Nephrol Dial Transplant 2013; 28:2841-2850.

  • Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG. Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes. N Engl J Med 2011; 365:327-36.

  • Downs M, Tucker K, Christ-Schmidt H, Wittes J. Some practical problems in implementing randomization. Clin Trials 2010; 7:235-245.
  • Trefz FK, Burton B, Longo N, Casanova M, Gruskin D, Dorenbaum A, Kakkis E, Crombez E, Grange D, Harmatz P, Lipson M, Milanowski A, Randolph LM, Vockley J, Whitley C, Wolff J, Bebchuk J, Christ-Schmidt H, Hennermann J. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: A phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009; 154:700-707.
  • Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, Wendel U, Dorenbaum A, Bebchuk J, Christ-Schmidt H, Seashore M, Giovannini M, Burton BK, Morris AA. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet 2008; 146A:2851-2859.
  • Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, Whitley CB, Feillet F, Feigenbaum AS, Bebchuk JD, Christ-Schmidt H, Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007; 370:504-510.
  • Wendler D, Kington R, Madans J, Van Wye G, Christ-Schmidt H, Pratt LA, Brawley OW, Gross CP, Emanuel E. Are racial and ethnic minorities less willing to participate in health research? PLoS Medicine 2006; 3:0201-0209.
  • Wittes J, Holmgren E, Christ-Schmidt H, Bajamonde A. Making independence work: Monitoring the bevacizumab colorectal cancer clinical trial. Data monitoring in clinical trials, a case studies approach. Springer, 360-367, 2006.
  • Christ-Schmidt H, Downs M. A SAS Macro to Generate Enhanced Kaplan Meier Plots. Proceedings of the Eighteenth Annual Conference of the Northeast SAS Users Group 2004.
  • Christ-Schmidt H, Downs M. A SAS Macro to Generate Enhanced Kaplan Meier Plots. Proceedings of the Thirtieth Annual Conference of the SAS Users Group International Conference 2004.
  • Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak J, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik J, Vaughn D, Innis B, Saluzzo J, Hoke CJ. Safety and immunogenicity of attenuated dengue virus vaccines (aventis pasteur) in human volunteers. Vaccine 2001; 19:3170-3188.